| 220 mg dabigatran etexilate initiated post-surgery | 150 mg dabigatran etexilate initiated post-surgery | 40 mg enoxaparin initiated 12 h pre-surgery |
---|---|---|---|
RE-MODELâ„¢trial (knee replacement) | |||
Total VTE and all-cause mortality (primary efficacy end-point) | 183/503 (36.4%) | 213/526 (40.5%) | 193/512 (37.7%) |
Major bleeding | 10/679 (1.5%) | 9/703 (1.3%) | 9/694 (1.3%) |
RE-NOVATE ® trial (hip replacement) | |||
Total VTE and all-cause mortality (primary efficacy end-point) | 53/880 (6.0%) | 75/874 (8.6%) | 60/897 (6.7%) |
Major bleeding | 23/1146 (2.0%) | 15/1163 (1.3%) | 18/1154 (1.6%) |
RE-NOVATE ® II trial (hip replacement) | |||
Total VTE and all-cause mortality (primary efficacy end-point) | 61/792 (7.7%) | - | 69/785 (8.8%) |
Major bleeding | 14/1010 (1.4%) | - | 9/1003 (0.9%) |